|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The anti-apoptotic Bcl-2 family protein myeloid cell leukemia-1 (Mcl-1) plays an important role in breast cancer cell survival and chemoresistance.
|
28301598 |
2017 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review will focus on the role of Bcl-2 family proteins in normal breast development, breast tumorigenesis and acquired resistance to breast cancer treatment strategies, while highlighting Mcl-1 as a promising target to improve breast cancer tumor cell killing.
|
25784482 |
2015 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, we demonstrate substantial synergy between navitoclax and MCL-1 siRNA, the direct MCL-1 inhibitor A-1210477, or the indirect MCL-1 inhibitor flavopiridol, highlighting the therapeutic potential for inhibiting BCL-XL and MCL-1 in breast cancer.
|
26013319 |
2015 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Relationship of Mcl-1 isoforms, ratio p21WAF1/cyclin A, and Jun kinase phosphorylation to apoptosis in human breast carcinomas.
|
12359245 |
2002 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our date demonstrated that enforced miR-519d expression enhanced the cisplatin-induced apoptosis through the MCL-1 dependent mitochondria pathway in breast cancer stem cells.
|
28423543 |
2017 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prototypical members of SR/hnRNP families, SRSF1 and hnRNP A1, promote synthesis of anti-apoptotic splice variants of Bcl-x and Mcl-1, which results in attenuation of programmed cell death in breast cancer and chronic myeloid leukemia.
|
28315432 |
2017 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since the anti-apoptotic Bcl-2 family protein myeloid cell leukemia-1 (Mcl-1) plays an important role in breast cancer cell survival and chemoresistance, we investigated if PKCη regulates Mcl-1 level.
|
28939105 |
2017 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Silencing of both Mcl-1 and BOK rescued the effect of Mcl-1 silencing on breast cancer cell growth, suggesting that BOK is important for attenuating cell growth in the absence of Mcl-1.
|
29156771 |
2017 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer.
|
30374681 |
2019 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
ABT-737 alone had no effect on apoptosis, but cafestol markedly enhanced ABT-737-mediated apoptosis in Mcl-1-overexpressed Caki cells, human glioma U251MG cells, and human breast carcinoma MDA-MB231 cells.
|
25375379 |
2014 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to investigate whether miR-193b mediated the resistance of breast cancer cells to doxorubicin by targeting myeloid cell leukemia-1 (MCL-1).
|
26526790 |
2015 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In summary, our study showed that miR-363 was a negative regulator of Mcl-1 expression, and the combination of miR-363 and cisplatin may be a novel approach in the treatment for breast cancer.
|
25416050 |
2014 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo.
|
20855960 |
2010 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We investigated the role of FBXW7 and their substrates MCL1 and PLK1 in regulating the apoptotic response to paclitaxel treatment in breast cancer cells and their expression in breast cancer tissues.
|
27409838 |
2016 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In summary, Bay 61-3606 downregulates Mcl-1 expression in breast cancer cells and sensitizes cancer cells to TRAIL-mediated apoptosis.
|
26720004 |
2015 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Downregulation of Mcl-1 by daunorubicin pretreatment reverses resistance of breast cancer cells to TNF-related apoptosis-inducing ligand.
|
22554523 |
2012 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
By tilting the balance of pro- to antiapoptotic signals in the mitochondria, dual inhibition of MCL-1 and BCL-X<sub>L</sub> also sensitizes breast cancer cells to standard-of-care cytotoxic and targeted chemotherapies.
|
27974663 |
2016 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
It was further explored that miR-26a increased sensitivity of breast cancer cells to paclitaxel in which MCL-1 was involved.
|
23750239 |
2013 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
3-Chloroplumbagin Induces Cell Death in Breast Cancer Cells Through MAPK-Mediated Mcl-1 Inhibition.
|
31404252 |
2019 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results demonstrate that breast cancers rapidly deploy Mcl-1 to promote cell survival, particularly when challenged with blockade of other Bcl-2 family members, warranting the continued development of Mcl-1-selective inhibitors for targeted tumor cell killing.<b>Implications:</b> Mcl-1 levels predict breast cancer response to inhibitors targeting other Bcl-2 family members, and demonstrate the key role played by Mcl-1 in resistance to this drug class.<i></i>.
|
28039357 |
2017 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, our findings provide a strong rationale for the clinical evaluation of MCL-1 inhibitors in breast cancer.
|
28768804 |
2017 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have demonstrated that inhibiting MCL-1 is efficacious in suppressing tumour progression in pre-clinical models of breast cancer and revealed that in addition to its role in cell survival, MCL-1 modulated cellular invasion.
|
29166822 |
2018 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results indicate that the EGF induced activation of Elk-1 is an important mediator of Mcl-1 expression and cell survival and therefore a potential therapeutic target in breast cancer.
|
21258408 |
2011 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data demonstrate that high MCL-1 protein expression is associated with poor outcome in breast cancer and support the therapeutic targeting of MCL-1 in this disease.
|
29339815 |
2018 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this study, to our knowledge, we provide for the first time mechanistic evidence that VB1-induced apoptosis in the human breast cancer line, MDA-MB-231, is associated with the generation of reactive oxygen species (ROS), the activation of caspases and the modulation of the expression of myeloid leukemia cell differentiation protein 1 (Mcl‑1), B cell lymphoma‑2 (Bcl-2) and Bcl-2-associated X (Bax) proteins.
|
24276280 |
2014 |